Quick-Med Technologies, Inc. Signs Joint Development Agrement with a Leading Provider of Health Care Products

GAINESVILLE, Florida, April 10, 2008 – Quick-Med Technologies announced today that it has entered into a joint development agreement to develop applications of its NIMBUS® antimicrobial technology with one of the world’s leading providers of health care products.

“We are very pleased to be working with this global, high growth health care company,” said J. Ladd Greeno, Chief Executive Officer of Quick-Med Technologies. “This collaboration is an important validation of the unique capabilities of our NIMBUS technology.”

The specific terms of the agreement were not disclosed.

About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. (OTC Bulletin Board: QMDT) is a life sciences company that is developing broad-based technologies for the healthcare and consumer markets. The Company's two core product groups under development are (1) NIMBUS®, a technology employing advanced polymers that can be used in a wide range of applications from advanced wound care to industrial and consumer products; and (2) MultiStat™ family of advanced patented methods and compounds, shown to be effective in key skin care therapy applications for cosmetic, military, and medical markets. For more information, see: www.quickmedtech.com

For additional further information, please contact QMT:

CONTACT:
Natasha A. Sorobey, Investor & Media Relations
Tel. (888) 835.2211 Ext 107
Email: info@quickmedtech.com

Natasha A. Sorobey -- Corporate & Investor Relations (Canada)
Phone: (403) 203-4748
Email: nsorobey@quickmed-technologies.com

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology is intended to identify forward-looking statements involve risks and uncertainties, including launch and approval of the potential products described herein and the Company¹s results of operations. The Company is also subject to other risks as detailed from time-to-time in the Company¹s SEC filings.